Publications by authors named "Marilyn M Giacomini"

Understanding transporter-mediated drug-drug interactions is an integral part of risk assessment in drug development. Recent studies support the use of hexadecanedioate (HDA), tetradecanedioate (TDA), coproporphyrin (CP)-I, and CP-III as clinical biomarkers for evaluating organic anion-transporting polypeptide (OATP)1B1 (SLCO1B1) inhibition. The current study investigated the effect of OATP1B1 genotype c.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates how certain Janus kinase inhibitors (JAKi) affect thiamine transport, which has implications for Wernicke's encephalopathy and the halted development of fedratinib.
  • It was found that only JAKi with a 2,4-diaminopyrimidine structure can inhibit thiamine transport, with fedratinib being a significant inhibitor compared to others like AZD1480 and cerdulatinib.
  • Results also revealed that some compounds, including the antibiotic trimethoprim, can inhibit thiamine uptake, and both fedratinib and trimethoprim act as substrates for thiamine transporters, affecting their behavior in the body.
View Article and Find Full Text PDF

The biguanide metformin is widely used as first-line therapy for the treatment of type 2 diabetes. Predominately a cation at physiological pH's, metformin is transported by membrane transporters, which play major roles in its absorption and disposition. Recently, our laboratory demonstrated that organic cation transporter 1, OCT1, the major hepatic uptake transporter for metformin, was also the primary hepatic uptake transporter for thiamine, vitamin B1.

View Article and Find Full Text PDF

Myofibroblasts are the major source of extracellular matrix components that accumulate during tissue fibrosis, and hepatic stellate cells (HSCs) are believed to be the major source of myofibroblasts in the liver. To date, robust systems to genetically manipulate these cells have not been developed. We report that Cre under control of the promoter of Pdgfrb (Pdgfrb-Cre) inactivates loxP-flanked genes in mouse HSCs with high efficiency.

View Article and Find Full Text PDF

Gene fusions, like BCR/ABL1 in chronic myelogenous leukemia, have long been recognized in hematologic and mesenchymal malignancies. The recent finding of gene fusions in prostate and lung cancers has motivated the search for pathogenic gene fusions in other malignancies. Here, we developed a "breakpoint analysis" pipeline to discover candidate gene fusions by tell-tale transcript level or genomic DNA copy number transitions occurring within genes.

View Article and Find Full Text PDF

Transforming Growth Factor Beta (TGF-β) is involved in regulating many biological processes and disease states. Cells secrete cytokine as a latent complex that must be activated for it to exert its biological functions. We previously discovered that the epithelial-restricted integrin α(v)β(6) activates TGF-β and that this process is important in a number of in vivo models of disease.

View Article and Find Full Text PDF